Compare QDEL & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | NEO |
|---|---|---|
| Founded | 1979 | 2001 |
| Country | United States | United States |
| Employees | N/A | 2500 |
| Industry | Medical Specialities | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2022 | 2008 |
| Metric | QDEL | NEO |
|---|---|---|
| Price | $11.93 | $9.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $28.25 | $13.38 |
| AVG Volume (30 Days) | ★ 2.2M | 2.0M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,730,200,000.00 | N/A |
| Revenue This Year | $3.51 | $10.63 |
| Revenue Next Year | $3.86 | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.92 | $4.72 |
| 52 Week High | $35.58 | $13.74 |
| Indicator | QDEL | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 60.46 |
| Support Level | $10.39 | $7.42 |
| Resistance Level | $12.85 | $10.82 |
| Average True Range (ATR) | 0.95 | 0.40 |
| MACD | 0.34 | 0.04 |
| Stochastic Oscillator | 70.14 | 89.45 |
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.